HPR157 Repurposed Drugs Launched Under the AMNOG in Germany: Effects on Benefit Assessment and Price Development
| Autor: | Sake, SM, Martyniszyn-Eiben, A, Zavatta, E, Glüsen, M, Berger, I, Schönermark, M |
|---|---|
| Zdroj: | In Value in Health December 2022 25(12) Supplement:S261-S261 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect